Research Reference
Retatrutide — Reconstitution & Research Guide
Retatrutide acts on glp-1 + gip + glucagon (triple agonist) and is studied for metabolic & body-weight research (phase 3 (investigational)). Below: what the research covers, how to reconstitute and verify a vial, and reference values from the literature — framed strictly for laboratory research.
Research use only. This page is a research and laboratory-reference resource — mechanism, reconstitution math, and reference values from published research. It provides no human, veterinary, therapeutic, diagnostic, or administration guidance. Compounds sold by Renova Wellness™ are not approved for human or animal consumption.
Quickstart
Category
metabolic
Vial sizes
10 / 15 / 20 / 30 / 40 mg
Reconstitution
10 mg in 1 mL → 10 mg/mL
Reference amount
2–12 mg (research literature) · ~20 units/draw
Per-batch COA
HPLC purity + mass-spec identity
Storage
Frozen (lyophilized) · 2–8°C reconstituted
What the research covers
Retatrutide acts on GLP-1 + GIP + glucagon (triple agonist) and is studied for metabolic & body-weight research. Research status: phase 3 (investigational). The evidence base is largely preclinical and mechanistic; this section summarizes what published work has examined, not outcomes for any product. See the full cited overview in the Retatrutide research guide.
Reconstitution & calculator
Reconstitution is arithmetic: concentration = mg ÷ mL. A tidy option is 1 mL for a round 10 mg/mL (1 mg = 10 units). The tool below is pre-loaded for Retatrutide; type a vial and reference amount and it returns the clean-tick water options, U-100 units, and draws per vial.
Nova — Renova’s research assistant
Guided reconstitution · ⚡ Powered by Claude
- 1Draw 1 mL of bacteriostatic water (the volume set in the calculator above) and add it slowly down the inside wall of the vial.
- 2Swirl gently until fully dissolved — do not shake. The reconstituted solution should be clear.
- 3Label the vial with the date.
- 4Refrigerate at 2–8°C, protected from light, and use within the handling window below.
Supply reference
At a 2 mg reference amount, a 10 mg vial yields about 5 draws — roughly 1.7 weeks at 3 draws/week. Adjust the amount and cadence in the calculator to plan your own research schedule.
Shop Retatrutide →Storage & handling
- • Lyophilized: keep frozen, protected from light and moisture.
- • Reconstituted: refrigerate at 2–8°C, protected from light.
- • Avoid freeze–thaw of the reconstituted solution.
- • Allow a frozen vial to reach room temperature before opening. Read the storage guide.
Verify before you trust it
Every Retatrutide lot is third-party tested and ships with its own per-batch Certificate of Analysis — HPLC purity and mass-spectrometry identity, tied to the lot number on your vial. Don’t take our word for it: confirm the exact lot yourself.
Retatrutide FAQ
How do I reconstitute Retatrutide?+
Retatrutide ships lyophilized and is reconstituted with bacteriostatic water. Divide the mg in the vial by the mL of water for the concentration: a 10 mg vial in 1 mL is 10 mg/mL. Use the calculator on this page for other volumes. This is laboratory math, not a protocol.
What are the reference amounts for Retatrutide?+
In the research literature Retatrutide is commonly referenced around 2–12 mg (research literature). At a 10 mg vial in 1 mL that's about 20 units on a U-100 syringe for a 2 mg draw. These are reference values from published research — not a dose, recommendation, or instruction.
How is Retatrutide verified for purity?+
Every Renova Wellness lot ships with its own per-batch Certificate of Analysis — identity by mass spectrometry and purity by HPLC, tied to the lot number on the vial. You can confirm any lot yourself on the verification page before it leaves the bench.
How should Retatrutide be stored?+
Lyophilized vials are kept frozen, protected from light and moisture. Once reconstituted with bacteriostatic water, the solution is refrigerated at 2–8°C, protected from light, and avoided from freeze–thaw cycles. General laboratory-handling reference only.
Research references
Primary literature for Retatrutide. Provided for scientific context only — not medical or dosing guidance.
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315 →
- Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. PMID 37385280 →
Research Use Only
Sold strictly for in-vitro laboratory and scientific research. Not for human or animal consumption. Not a drug, supplement, or medical device. These statements have not been evaluated by the FDA.